clofibrate
Trade name: atromid-s
Approved
Feb 8, 1967
Clofibrate is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 7 marketing orgs
Earliest trial started Apr 1, 1965 (NCT00000482)
Timeline
1960s
- Jan 1, 1965
Earliest Phase 3 Sponsor(trial)
- Feb 8, 1967
Wyeth — Earliest FDA Approval
- Feb 8, 1967
American Home Products — NDA Secondary Org
- Feb 8, 1967
Wyeth — NDA Organization
1980s
- Jun 16, 1986
Upsher-Smith Laboratories — Marketing Organization
- Sep 18, 1987
Watson Pharmaceuticals — Marketing Organization
1990s
- Jul 25, 1991
Teva — Marketing Organization
- Mar 20, 1992
Banner Pharmacaps — Marketing Organization
Indications
Approved for
Mechanism of action
Approval history
- approvedPriority reviewFeb 8, 1967
Chemistry & pharmacology
SMILES
COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1- Mol. weight
- 387.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL279229 ↗
- WikipediaClofibrate ↗
- ChEMBLCHEMBL565 ↗
- ChEMBLCHEMBL1256716 ↗
Also known as
- 2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester
- 2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester
- 2-(p-chlorophenoxy)-2-methylpropionic acid ethyl ester
- 2-(p-chlorophenoxy)-2-methylpropionic acid ethyl ester
- alpha-(p-chlorophenoxy)isobutyric acid, ethyl ester
- alpha-(p-chlorophenoxy)isobutyric acid, ethyl ester
- alpha-p-chlorophenoxyisobutyryl ethyl ester
- alpha-p-chlorophenoxyisobutyryl ethyl ester
- atromid
- atromid
- atromid-s
- atromid-s
- atromid-s
- ay-61123
- ay-61123
- chlorfenisate
- chlorfenisate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrate
- clofibrato
- clofibrato
- clofibratum
- clofibratum
- elpi
- elpi
- epib
- epib
- ethyl 2-(p-chlorophenoxy)isobutyrate
- ethyl 2-(p-chlorophenoxy)isobutyrate
- ethyl chlorophenoxyisobutyrate
- ethyl chlorophenoxyisobutyrate
- ethyl clofibrate
- ethyl clofibrate
- ici-28257
- ici-28257
- lipavil
- lipavlon
- lipofacton
- lipofacton
- lipomid
- liprin
- liprin
- liprinal
- miscleron
- misclerone
- p-chlorophenoxyisobutyric acid ethyl ester
- ticlobran
- xyduril
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000483 | N/A | Jun 1, 1981 | National Heart, Lung, and Blood Institute (NHLBI), University of Maryland |
| NCT00000482 | Phase 3 | Apr 1, 1965 | National Heart, Lung, and Blood Institute (NHLBI), University of Maryland |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 2 | 2 | 1965 |
| University of Maryland | Academic/Hospital | 2 | 0 | 2 | 1965 |
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA2 | Feb 8, 1967 |
| Banner Pharmacaps | For profit | MKTG | Mar 20, 1992 |
| Sandoz | For profit | MKTG | — |
| Teva | For profit | MKTG | Jul 25, 1991 |
| Upsher-Smith Laboratories | For profit | MKTG | Jun 16, 1986 |
| Watson Pharmaceuticals | For profit | MKTG | Sep 18, 1987 |
| Wyeth | For profit | NDA | Feb 8, 1967 |